Author

H. C. Keun

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 2 Organism:mouse· 2 Approach:statistical model· 2

Frequent Co-Authors

A. Nijhuis· 2 shared S. Spear· 2 shared Y. Xu· 2 shared A. Benito· 1 shared A. Montoya· 1 shared A. P. Costa-Pereira· 1 shared A. P. Siskos· 1 shared A. Sikka· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Nijhuis

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Heme oxygenase-1 expressing omental macrophages as a therapeutic target in ovarian high grade serous carcinoma

S. Spear, O. Le Saux, H. B. Mirza, K. Tyson, J. Bickel, F. Grundland Freile, A. P. Siskos, C. Balcells, J. B. Walton, C. Woodman, D. P. Ennis, N. Iyer, C. Aguirre Hernandez, Y. Xu, P. Spiliopoulou, , I. A. McNeish

This study identifies HMOX1-expressing omental macrophages as a therapeutic target and biomarker for poor prognosis ovarian high-grade serous carcinoma.

bioRxiv · Jul 18, 2023 · PreprintCancer Biology

Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma

Y. Xu, S. Spear, Y. Ma, M. P. Lorentzen, M. Gruet, F. McKinney, Y. Xu, C. Wickremesinghe, M. Shepherd, I. McNeish, H. C. Keun, A. Nijhuis

This study shows that combining RBM39 degraders with PARP inhibitors improves PARP inhibitor response in ovarian cancer, regardless of BRCA1/2 status.

bioRxiv · Jan 18, 2023Cancer Biology

Indisulam targets RNA splicing and metabolism to serve as a novel therapeutic strategy for high-risk neuroblastoma

A. Nijhuis, A. Sikka, O. Yogev, L. Herendi, C. Eckold, G. Valbuena, Y. Liu, E. Kouloura, E. Poon, B. Martins da Costa, A. Benito, H. Kramer, A. Montoya, D. Carling, E. J. Want, , H. C. Keun

This study shows that indisulam, a sulphonamide, targets RNA splicing and metabolism to inhibit neuroblastoma growth and achieve complete tumor remission in preclinical models.

bioRxiv · Dec 18, 2020Cancer Biology